83831-64-5

Usage

InChI:InChI=1/C9H12N4O7/c10-5-1-2-12(9(16)11-5)8-7(20-13(17)18)6(15)4(3-14)19-8/h1-2,4,6-8,14-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1

Upstream product

• 83831-66-7 1-(3,5-di-O-acetyl-2-O-nitro-β-D-arabinofuranosyl)-N⁴-acetylcytosine 
• 50896-84-9 2,2'-anhydro-1-(3,5-di-O-acetyl-β-D-arabinofuranosyl)cytosine hydrochloride 
• 13241-19-5 N⁴,O^3',O^5'-Triacetyl-1-β-D-arabinofuranosylcytosine 
• 2914-23-0 barium methoxide 

Relevant academic research and scientific papers

2'-O-Nitro-1-β-D-arabinofuranosylcytosine. A New Derivative of 1-β-D-Arabinofuranosylcytosine That Resists Enzymatic Deamination and Has Antileukemic Activity

To overcome the susceptibility of the anticancer drug 1-β-D-arabinofuranosylcytosine (ara-C) to enzymatic deamination, and hence deactivation, we prepared the 2'-O-nitro-1-β-D-arabinofuranosylcytosine (termed nitrara-C) and evaluated it for biological activity.Nitrara-C was resistant to enzymatic deamination and inhibited the proliferation of several strains of human leukemic T and B lymphoblasts grown in culture.Moreover, it substantially extended the life spans of mice with L1210 leukemia.Studies with ara-C-resistant human leukemic lymphoblasts deficient in deoxycytidine kinase activity disclosed that the inhibitory activity of the new compound depends on its phosphorylation.

Nitro-substituted 1-β-D-arabinofuranosylcytosines

1-(2-O-Nitro-β-D-arabinofuranosyl)cytosine and salts, anti-leukemics.